Open-Label, Multicenter, Phase I Study to Assess the Safety of P-BCMA-101 in Subjects with Relapsed / Refractory Multiple Myeloma MM Followed by a Phase II Assessment of Response and Safety PRIME
A Safety and Efficacy Study of JNJ?68284528 ciltacabtagene autoleucel Out?of?Specification OOS for Commercial Release in Patients with Multiple Myeloma
Phase I BCMA CAR T Trial in Relapsed or Refractory Multiple Myeloma Using our Next Generation of Investigational CAR-T Product Generated by a Unique Manufacturing Platform NEX-T
Expanded Access Program for belantamab mafodotin in Patients with Relapsed/Refractory Multiple Myeloma who are Refractory to a Proteasome Inhibitor, and an Immunomodulatory Agent, and an Anti-CD38 Antibody